Definiens AG To Demonstrate Use Of Tissue Phenomics In Prostate Cancer

New Data Based on Spatial Immune Cell Patterns to be Presented at Immunotherapy in Cancer Conference

MUNICH--(BUSINESS WIRE)--Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced that new findings for the development of prostate cancer diagnosis and treatment will be presented at the Immunotherapy in Cancer Conference (ITOC3) in Munich, Germany, March 21-23, 2016. Two posters demonstrating the use of Tissue Phenomics to find meaningful tissue patterns and develop tests for patient diagnostics will be presented. Additionally, the company will also be demonstrating the “Tissue Phenomics Approach,” allowing visitors an overview of how Definiens can stratify patients and improve Kaplan-Meier curves. The title and schedule of the posters are:

“Discovery of novel biomarkers based on spatial immune cell patterns: A disease-overarching image mining approach bridging biopsy evaluation in oncoimmunology and transplantation medicine”

Title: “Tumor-associated macrophages as a prognostic marker for prostate cancer progression”

Poster Session: Immune Regulation

Poster#: 27

Presented by Maria Athelogou

Title: “Discovery of novel biomarkers based on spatial immune cell patterns: A disease-overarching image mining approach bridging biopsy evaluation in oncoimmunology and transplantation medicine”

Poster Session: Monitoring of Immunotherapy

Poster#: 82

Presented by: Ralf Schönmeyer

“Immunotherapy is changing the way we think about treating cancer,” said Ralf Huss, Chief Medical Officer of Definiens. “As we understand more about the importance of specific immune cell interactions in different compartments of the tumor micro-environment, our Tissue Phenomics approach integrates big data and intelligent mining approaches to become increasingly powerful in understanding the signatures that are also clinically meaningful. As a pathologist, I am particularly excited about the breakthroughs that these posters represent in the possible future of patient care.”

Definiens will be exhibiting at booth #C01 at the Cancer Conference. For more detailed information on the conference, visit: http://itoc-conference.eu/

About Definiens:

Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit:www.definiens.com.

Contacts

Media
Affect
Jonathan Moll, +1 212 398 9680
jmoll(at)affect.com

Back to news